Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16638)	2/16/2004 7:41:48 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Well one thing you do understand about biotech is the lack of transparency. I can tell you this though, it sure looks like dna/sra/xoma have been very tight lipped about raptiva the platform. Go ask them and see how they will stonewall you. They might as well employ sargent schultz in the PR dept. VBG

To: aknahow who wrote (16638)	2/18/2004 12:17:04 PM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

George, a few questions. Will Citigroup now demand a seat or seats on the board of Xoma? Is this stake a prelude to a merger or buyout with Citigroup having a say in it? Do other institutions pay any attention to these type of accumulations? Did Citigroup soak up all these shares just because of Raptiva? Why would Citigroup invest in Xoma when we STILL don't know the crohn's numbers? Just my opinion BUT I think they are in it for the ACNE XMP.629 possibilities AND remember the pure gravy that comes in IF Serono gets Raptiva approved in all those other countries.